Bausch Health Companies (BHC) has notable insider buying

Bausch Health Companies (T:BHC)

Bausch Health Companies Inc. (BHC) has a high amount of executive buying compared to its large-cap peers over the past three months. Paul Herendeen, CFO, acquired 50,000 Common Shares on a direct ownership basis at a price of $22.370USD through an exercise of rights on August 23rd, 2018. This represents a $1,461,097 investment into the company's shares and an account share holdings change of greater than 100%.

Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis and other dermatoses. It also offers a selection of aesthetic medical devices that address a variety of conditions, including facial wrinkles, acne, pigmentation conditions and laser hair removal, among others. The gastrointestinal (GI) segment offers products that treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea and ulcerative colitis, among others. Its eye health products are marketed in the following categories: Contact Lens, Pharmaceutical Products and Surgical.